Patient Voice

1267 Getting a Kidney: Where Is Patient Choice?
Michael “Jack” Lennon
See related article on page 1363.

Editorials

1269 Unraveling the Mysteries of CKD of Uncertain Etiology
Pablo Garcia and Shuchi Anand
See related article on page 1293.

1272 Transplant Nephrology
Michel Chonchol, Orlando M. Gutierrez, Mahboob Rahman, David M. Charytan, and Mitchell Rosner
See related article and Perspectives on pages 1372, 1403, and 1407, respectively.

1275 Mitigating Pain in People Undergoing Hemodialysis
Sara N. Davison
See related article on page 1337.

1278 Improving the Utilization of Deceased Donor Kidneys by Prioritizing Patient Preferences
Sumit Mohan and S. Ali Husain
See related article on page 1363.

1281 Advancing Kidney Health Equity: Influences of Gender-Affirming Hormone Therapy on Kidney Function
Dinushika Mohottige and Delphine S. Tuot
See related article on page 1305.

Original Articles

Chronic Kidney Disease

1284 Urine Uromodulin as a Biomarker of Kidney Tubulointerstitial Fibrosis
Hannah Melchinger, Frida Calderon-Gutierrez, Wassim Obeid, Leyuan Xu, Melissa M. Shaw, Randy L. Luciano, Michael Kuperman, Gilbert W. Moeckel, Michael Kashgarian, F. Perry Wilson, Chirag R. Parikh, and Dennis G. Moledina

1293 Potential Mechanisms Involved in Chronic Kidney Disease of Unclear Etiology
Michael W. Holliday Jr., Qingtian Li, Edlyn C. Bustamante, Jingbo Niu, Luping Huang, Ilse M. Espina, Jose R. Dominguez, Luan Truong, Kristy O. Murray, Lei Fan, Samaya J. Anumudu, Maulin Shah, Rebecca S.B. Fischer, Chandan Vangala, Sreedhar Mandayam, Jose Perez, Jenny S. Pan, Sehrish Ali, Ahmed A. Awan, and David Sheikh-Hamad
See related editorial on page 1269.

Clinical Nephrology

1305 The Effect of Gender-Affirming Hormone Therapy on Measures of Kidney Function: A Systematic Review and Meta-Analysis
Emily Krupka, Sarah Curtis, Thomas Ferguson, Reid Whitlock, Nicole Askin, Adam C. Millar, Marshall Dahl, Raymond Fung, Sofia B. Ahmed, Navdeep Tangri, Michael Walsh, and David Collister
See related editorial on page 1281.
<table>
<thead>
<tr>
<th>Page</th>
<th>Topic</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1316</td>
<td>Glomerular and Tubulointerstitial Diseases</td>
<td>Automated Prediction of Kidney Failure in IgA Nephropathy with Deep Learning from Biopsy Images</td>
<td>Francesca Testa, Francesco Fontana, Federico Pollastri, Johanna Chester, Marco Leonelli, Francesco Giaroni, Fabio Caufieri, Federico Boleti, Elena Mancini, Maurizio Nordio, Paolo Sacco, Giulia Ligabue, Silvia Giovannella, Maria Ferrri, Gaetano Alfano, Loreto Cessaldeko, Simonetta Cimino, Gabriele Donati, Costantino Crana, and Riccardo Magistrini</td>
</tr>
<tr>
<td>1337</td>
<td></td>
<td>Effect of Music in Reducing Pain during Hemodialysis Access Cannulation: A Crossover Randomized Controlled Trial</td>
<td>Emi Inayama, Yosuke Yamada, Masatsugu Kishida, Mineaki Kitamura, Tomoya Nishino, Keiko Ota, Kanae Takahashi, Ayumi Shintani, and Tatsuyoshi Ikenoue</td>
</tr>
<tr>
<td>1363</td>
<td></td>
<td>Patient Preferences for Waiting Time and Kidney Quality</td>
<td>Sanjay Mehrotra, Juan Marcos Gonzalez, Karolina Schantz, Jui-Chen Yang, John J. Friedewald, and Richard Knight</td>
</tr>
<tr>
<td>1385</td>
<td>Critical Care Nephrology and Acute Kidney Injury</td>
<td>Acute Kidney Injury in Critically Ill Patients with Cancer</td>
<td>Shruti Gupta, Prakash Gudsoorkar, and Kenar D. Jhaveri</td>
</tr>
<tr>
<td>1399</td>
<td>Kidney Case Conference: How I Treat</td>
<td>Choosing the Right Treatment in Patients with Lupus Nephritis</td>
<td>Juan Manuel Mejia Vilet, Zhi-Hong Liu, and Tak Mao Chan</td>
</tr>
<tr>
<td>1403</td>
<td>Perspectives</td>
<td>The Importance of Transplant Nephrology to a Successful Kidney Transplant Program</td>
<td>Sharon M. Moe, Daniel C. Brennan, Mona D. Doshi, Robert S. Gaston, Susan B. Gurley, Muhammad A. Mujtaba, Rebecca J. Schmidt, Mark S. Segal, J. Kevin Tucker, Alexander C. Wiseman, and Michelle A. Josephson</td>
</tr>
<tr>
<td>1407</td>
<td></td>
<td>Existing Transplant Nephrology Compensation Models and Opportunities for Equitable Pay</td>
<td>Michelle A. Josephson, Alexander C. Wiseman, J. Kevin Tucker, Mark S. Segal, Rebecca J. Schmidt, Muhammad A. Mujtaba, Susan B. Gurley, Robert S. Gaston, Mona D. Doshi, Daniel C. Brennan, and Sharon M. Moe</td>
</tr>
</tbody>
</table>
On the Cover

What is the diagnosis?

A 50-year-old male presented with loss of appetite, dyspnea, and AKI following coronavirus 2019 (COVID-19) infection 3 months ago. The AKI required hemodialysis support. Other medications at the time of presentation included erythromycin 500 mg/day, an oral corticosteroid, and telmisartan 20 mg daily for hypertension. Fundus examination was unremarkable. Routine urine analysis showed 1+ protein and no cellular elements. Urine protein-creatinine ratio and serum creatinine were 0.6 g/g and 7.8 mg/dL, respectively. Earlier records documented normal kidney function 1 year ago. Of note, it was discovered that the patient was taking a vitamin C supplement 1 g/day that was initiated during COVID-19 illness and continued for 3 months. Biopsy was performed in view of nonrecovery of kidney function at 3 months.

Image Description:

Kidney biopsy revealed diffuse acute tubular injury with attenuated epithelium lining. Most of the tubules showed fan-shaped transparent crystals arranged within tubular lumens distorting luminal contours. Crystals are birefringent under polarizer. Mild degree of interstitial fibrosis is noted. Glomerular and vascular compartments showed nonspecific findings. Immunofluorescence was negative with entire panel (IgG/A/M, C3/C1q, Kappa/Lambda) of antisera.

Teaching Points:

AKI in patients infected with COVID-19 may be associated with multifactorial etiologies such as sepsis, hypoperfusion, cytokine storm, possible direct cytopathic effect of the virus, thrombotic microangiopathy, pigment nephropathy, and therapeutic complications. Kidney complications may also be secondary to antibiotics and vitamin C supplements. The unproven rationale for supplementing vitamin C in COVID-19 is to prevent sepsis-induced cytokine production and reduce proinflammatory biomarkers and disease-related mortality. However, endogenous conversion of ascorbic acid to oxalate causes hyperoxaluria. Fontana et al. have reported two cases of intravenous vitamin C supplementation–induced oxalate nephropathy with dosage of 50 mg/kg four times per day in patients with COVID-19 infection (1). We believe that continued overdosage of vitamin C led to formation of oxalate crystals. Less than half of patients with oxalate nephropathy require KRT and remain dialysis dependent. Our patient remained dialysis dependent at the end of 4 weeks despite withdrawal of vitamin C following biopsy findings. We attribute nonrecovery to the interstitial fibrosis noted on the histology and hence progressing to CKD. Clinicians should keep occurrence of oxalate nephropathy with vitamin C supplementation among the differentials of AKI in COVID-19 patients.

Reference:


(Image and text provided by Mahesha Vankalakunti, Manipal Hospital, Bengaluru, India; Kiran K. Gowda, Manipal Hospital, Bengaluru, India; and Madhusudan H. Chamnegowda, Mangala Hospital, Hassan, India)